COSA 2020: First-Line NALIRIFOX Shows Promise in Locally Advanced/Metastatic PDAC
The therapy will proceed to a comparison vs gemcitabine + nab-paclitaxel.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.